Latin American Symposium Future Perspectives in Pulmonary Hypertension.

Slides:

Advertisements

Similar presentations

ISHLT 2011 Pulmonary Hypertension Council Report Myung H. Park, MD April 16, 2011 San Diego, CA.

Advertisements

Clinical Reasoning Deficits Dr. Traci O’Connor Dr. Lisa Tekell.

World Conference on COPD Patients

Shared Decision Making & in Family Medicine &Patient Empowerment in Family Medicine Introduction to Primary Care: a course of the Center of Post Graduate.

Maria E. Suarez-Almazor, MD, PhD Houston CERTs Using Decision Aids to Enhance Shared-Decision Making.

Picture of my family – love to start talks in the comfort of my living room. Feel passionate about my girls and about this unique population of patients.

Nottingham West CCG - A Practice Perspective Dr James Read GP – The Manor Surgery, Beeston Mental Health Clinical Lead.

Is the failure of pulmonary gas exchange to maintain the normal arterial O2 and CO2 level. It is divided in to type I and II in relation to the presence.

African Treament Advocacy workshop - MRC 31/05/07 Doctor patient relationship Quality of Life By: Badru Male.

Graeme Thomson. Stem An 80 year old woman from home presents with fever, cough and collapse. She has a history of chronic renal failure, hypertension.

Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland,

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Arterial Hypertension J Am Coll Cardiol.

Heart Failure in Women Dr. Jennifer Haythe

Fig. 2. Clinical images of near total improvement cases. (A) No

Pulmonary hypertension

Upfront Combination Therapy vs Step-Up Approach for PAH:

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Clinical use of PAH drugs based on functional class

A Framework for Diagnosing and Treating CTEPH

Update on the Diagnosis and Management of CTEPH in Latin America

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Risk Stratification in PAH: What Do the Latest Data Suggest?

An Update on Oral Prostanoids: Advancing Care for PAH?

Identifying and Managing Dyspnea Associated With CTEPH

Setting the Stage – PAH Therapy Trials Current PAH Pharmacotherapies.

UNDERSTANDING RISK STRATIFICATION IN PAH:

Select Topics in Cardiovascular Medicine

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

New Treatments for CTEPH

Mitchell Schnall MD, PhD

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Improving Risk Assessment and Early Diagnosis in PAH

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

WHO Clinical Classification of PH Complex Cases in PH.

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Examining the Latest Evidence in PAH

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Current and Emerging Data in CTEPH

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

Preventing Clinical Events in PAH

Identifying Strategies for Improving Outcomes in Patients With CTEPH

Extended pericardiotomy avoids cardiopulmonary bypass during bilateral sequential lung transplantation Takahiro Oto, MD, Marc Rabinov, FRACS, Franklin.

Pulmonary Arterial Hypertension and Connective Tissue Disease

What's New in PAH?.

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the.

Pulmonary Hypertension Updates From 2018

Perspective on the Multidisciplinary Management of PAH

Live on PAH: Breathing Life Into Patients With PAH

CTEPH in Clinical Practice

When Good Isn't Good Enough

Therapy for Pulmonary Arterial Hypertension in Adults

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Prostacyclin Pathway Agents in Action

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Incorporating New PAH Treatments Into Clinical Practice

Clinical Comparisons in CTEPH

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Prevalence of pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) according to defect. Prevalence of pulmonary arterial.

Pulmonary Arterial Hypertension and Hospitalizations

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

უმაღლესი საგანმანათლებლო დაწესებულებების ავტორიზაცია:

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Schematic representations of pulmonary hypertension.

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Presentation transcript:

Latin American Symposium Future Perspectives in Pulmonary Hypertension

Program State of the art conferences Debates Controversies Future perspectives Quiz & Interactive sessions

State of the Art Conferences Management of PH: Current status Advances in the treatment: Riociguat Clinical studies: PATENT & LEPHT CTEPH: Riociguat development

Future Perspectives Session II: PH management in Latin America Current situation Research in Latin America Multidisciplinary approach Patient perspective Session III: CTEPH From diagnosis to treatment (interactive)

Debate I: Left Ventricle

Debate II: COPD

Debate III: Eisenmenger

Controversies in PAH 1. Pregnancy 2. Instable PH (acute state) 3. Combined treatment: sequential vs. upfront 4. Best imaging method to study the RV

Controversies PH management decisions Good decisions Informed Supported by best evidence Compatible with patients values Considers patients preferences Weigh pros and cons Practical Poor decisions Objective data inadequate Too few options considered Alternatives unclear Values and preferences unexplored Roles unclear Communication is poor

Simposio Latinoamericano Perspectivas Futuras en Hipertensión Pulmonar